 use L-dopa carbidopa metastatic malignant melanoma combination L-dopa carbidopa patients metastatic melanoma Maximum oral doses grams response patients evaluable response Toxicity considerable patients stopping treatment unacceptable gastrointestinal toxicity postural hypotension Contrary previous anecdotal reports evidence L-dopa/carbidopa treatment accelerated progression metastatic melanoma L-dopa/carbidopa ineffective therapy advanced melanoma maximum doses